221244-14-0
![221244-14-0 结构式](https://www.chemicalbook.com/CAS/GIF/221244-14-0.gif)
基本信息
Chebi:52309
PP1 ANALOG II
PP1 Analog II, 1NM-PP1
MUTANT KINASES INHIBITOR II
4-AMINO-1-TERT-BUYTL-3-(1-NAPHTHYLMETHYL)PYRAZOLO[3,4-D]PYRIMIDINE
4-AMINO-1-TERT-BUTYL-3-(1'-NAPHTHYLMETHYL)PYRAZOLO[3,4-D]PYRIMIDINE
1-tert-Butyl-3-(naphthalen-1-ylmethyl)-1H-pyrazolo[3,4-D]pyrimidin-4-amine
1-(1,1-Dimethylethyl)-3-(1-naphthalenylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
物理化学性质
熔点 | 175-176°C |
沸点 | 545.7±45.0 °C(Predicted) |
密度 | 1.25±0.1 g/cm3(Predicted) |
储存条件 | -20°C冷冻 |
溶解度 | 氯仿(微溶)、甲醇(微溶、加热) |
酸度系数(pKa) | 4.50±0.30(Predicted) |
形态 | 白色固体 |
颜色 | 白色至米色 |
安全数据
危险性符号(GHS) | ![]() ![]() GHS07,GHS03 |
警示词 | 警告 |
危险性描述 | H315-H319-H272 |
防范说明 | P501-P220-P210-P221-P264-P280-P302+P352-P370+P378-P337+P313-P305+P351+P338-P362+P364-P332+P313 |
1 NM-PP1价格(试剂级)
报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
2025/02/08 | HY-13942 | 1-NM-PP1 | 221244-14-0 | 1 mg | 401元 |
2025/02/08 | HY-13942 | 4-氨基1-叔丁基-3-(1'-萘甲基)吡唑并[3,4-D]嘧啶 1-NM-PP1 | 221244-14-0 | 5mg | 884元 |
2025/02/08 | HY-13942 | 4-氨基1-叔丁基-3-(1'-萘甲基)吡唑并[3,4-D]嘧啶 1-NM-PP1 | 221244-14-0 | 10mM * 1mLin DMSO | 972元 |
常见问题列表
IC50: 4.3 nM (v-Src-as1), 3.2 nM (c-Fyn-as1), 28 μM (v-Src), 1 μM (c-Fyn), 3.4 μM (c-Abl), 29 μM (CDK2), 24 μM (CAMKII), 120 nM (cAbl-as2), 5 nM (CDK2-as1), 8 nM (CAMKII-as1)
Cdk7 from Cdk7 as/as or Cdk7 +/+ cells is immunoprecipitated and tested its kinase activity towards both a Pol II CTD-containing fusion protein (GST-CTD) and human Cdk2. Cdk7 recovered from the mutant, but not the wild-type, cells is inhibited by 1-NM-PP1 (1-NMPP1), with an IC 50 of ~50 nM with either substrate. Replacement of wild-type Cdk7 with Cdk7 as/as also rendered growth of HCT116 cells sensitive to 1-NM-PP1. In the absence of 1-NM-PP1, the wild-type and Cdk7 as/as cells had population doubling times of ~17.9 and ~20.2 h, respectively, with similar cell-cycle distributions in asynchronous culture, indicating minimal impairment of Cdk7 function by the F91G mutation per se. The homozygous Cdk7 as/as cells are sensitive to 1-NM-PP1, however, with an IC 50 ~100 nM measured by cell viability (MTT) assays performed after 96 h of 1-NM-PP1 exposure. In contrast, wild-type HCT116 cells are resistant to 10 μM 1-NM-PP1. Addition of 10 μM 1-NM-PP1 retards G1/S progression by the mutant but not the wild-type cells. When added simultaneously with serum to the Cdk7 as/as cells, 1-NM-PP1 prevents any progression into S phase in the next 15 h. After 24 h, there is evidence of progression into S-phase by a fraction of Cdk7 as/as cells released from serum starvation directly into medium containing 1-NM-PP1, while a fraction remained in G1. The addition of 1-NM-PP1 3 h or 6 h after serum addition delays S-phase entry by ~7 h or by ~3 h, respectively.